Search results
Cholesterol drug ‘slows progression of eye disease in people with diabetes’
PA Media: Science via Yahoo News· 3 hours agoThe research, announced at the American Diabetes Association Scientific Sessions and published in...
Eli Lilly seeks FDA’s OK to expand Zepbound’s uses to include sleep apnea
Market Watch· 3 hours agoFor more than half of patients who use the common sleep-apnea therapy PAP, or positive airway...
Gan & Lee Pharmaceuticals to Present Groundbreaking Data on Three Innovative Products at the ...
The Pilot News· 4 days agoClick here to view this image from thepilotnews.com.
HighTide Therapeutics Presents Analyses of a Phase 2 T2DM Study at the ADA Scientific Sessions,...
NewMediaWire via Yahoo Finance· 5 hours agoROCKVILLE, MD and SHENZHEN, CHINA, - (NewMediaWire) - June 21, 2024 - HighTide Therapeutics, Inc....
New Weight-Loss Drugs and Devices Are Coming This Week
Barrons.com· 3 days agoWeight-loss breakthroughs all emerged from diabetes treatment. Meetings such as the coming American ...
Foods Diabetics Should Probably Stay Away From
MediaFeed via AOL· 11 hours agoBut it turns out that both have their downsides, and if a diabetic wants to maintain healthy insulin levels, it's probably best if they don't drink any...
Weight-loss drug Zepbound resolves sleep apnea in up to 52% of patients, Lilly says
Reuters via Yahoo News· 3 hours agoEli Lilly on Friday said its popular weight-loss drug Zepbound helped resolve moderate to severe...
ADA Scientific Sessions 2024 Go Beyond Glucose and Obesity
Medscape· 3 days agoThe American Diabetes Association (ADA) 84th Scientific Sessions, taking place June 21-24, 2024,...
Do Artificial Sweeteners Really Help People With Diabetes?
Medscape· 2 days agoIt seems intuitive that because people with type 2 diabetes (T2D) generally need to avoid sugar,...
T1D Exchange Announces 21 Real-World Data Presentations at the American Diabetes Association (ADA)...
The Martinsburg Journal· 4 days agoBOSTON, June 17, 2024 /PRNewswire/ -- T1D Exchange, a nonprofit organization that drives meaningful research and improvement in care and outcomes in type 1 and type 2 diabetes
